CGMS-A

Know Labs, Inc. Expands IP Leadership in Non-Invasive Diagnostics with New High Performance Glucose Sensor Patent

Retrieved on: 
Wednesday, January 4, 2023
Biotechnology, Technology, Other Health, Diabetes, Health, General Health, Pharmaceutical, Health Technology, Medical Devices, Hospitals, Hardware, Algorithm, IP, Abbott Laboratories, Patent, United States patent law, United States Patent and Trademark Office, Internal, NYSE, Investment, FDA, CGMS-A, MARD, Laboratory, YSI, Medical imaging, Medical device, Dexcom

The new patent extends the Know Labs IP portfolio to nearly 90 patents issued and pending, reinforcing the company’s position as the top worldwide IP holder in non-invasive blood glucose monitoring.

Key Points: 
  • The new patent extends the Know Labs IP portfolio to nearly 90 patents issued and pending, reinforcing the company’s position as the top worldwide IP holder in non-invasive blood glucose monitoring.
  • 11,529,077, titled “High Performance Glucose Sensor,” was just issued by the United States Patent and Trademark Office.
  • This patent explicitly designates a MARD range of 5.0% to 9.9% for Know Lab’s non-invasive diagnostics technology platform.
  • “The high accuracy of the [Know Labs] non-invasive glucose sensor described herein, when compared to lower accuracy glucose sensors such as minimally invasive CGMs and fingerstick glucose sensors, means that the [Know Labs’] non-invasive glucose sensor can be used as a standard or reference sensor against which the accuracy of other glucose sensors are gauged.

Digital Diabetes Management Market Size to Reach USD 37.8 Billion in 2030 | Emergen Research

Retrieved on: 
Wednesday, December 21, 2022
Digital technology, Data visualization, USD, World Health Organization, CGMS-A, Patient, Cyberattack, WHO, Diabetes, Obesity, Health, Dexcom, Roche, Digital, Eli Lilly and Company, Medtronic, Partnership, Growth, Zur Rose Group, Risk, DPP, Country, National Association Medical Staff Services, Prescription, Prevalence, Eating, Bayer, DM, Incidence, LifeScan, ICT, Medical device, Pharmaceutical industry

VANCOUVER, B.C., Dec. 21, 2022 /PRNewswire/ -- The digital diabetes management market size reached USD 13.6 Billion in 2021 and is expected to register a CAGR of 12.0% during the forecast period, according to latest analysis by Emergen Research .

Key Points: 
  • VANCOUVER, B.C., Dec. 21, 2022 /PRNewswire/ -- The digital diabetes management market size reached USD 13.6 Billion in 2021 and is expected to register a CAGR of 12.0% during the forecast period, according to latest analysis by Emergen Research .
  • As a result, the management and treatment of many diseases are depending on the widespread use of information and communication technology (ICT)-based digital health systems, which is driving the adoption of digital diabetes management services in the market.
  • Demand for digital diabetes management devices has significantly increased over the years due to the increasing prevalence of diabetes and obesity around the world.
  • The digital diabetes management market is expected to register a CAGR of 12.0% over the forecast period and revenue is projected to increase from USD 13.6 Billion in 2021 to USD 37.8 Billion in 2030.

Digital Diabetes Management Market Size to Reach USD 37.8 Billion in 2030 | Emergen Research

Retrieved on: 
Wednesday, December 21, 2022
Digital technology, Data visualization, USD, World Health Organization, CGMS-A, Patient, Cyberattack, WHO, Diabetes, Obesity, Health, Dexcom, Roche, Digital, Eli Lilly and Company, Medtronic, Partnership, Growth, Zur Rose Group, Risk, DPP, Country, National Association Medical Staff Services, Prescription, Prevalence, Eating, Bayer, DM, Incidence, LifeScan, ICT, Medical device, Pharmaceutical industry

VANCOUVER, B.C., Dec. 21, 2022 /PRNewswire/ -- The digital diabetes management market size reached USD 13.6 Billion in 2021 and is expected to register a CAGR of 12.0% during the forecast period, according to latest analysis by Emergen Research .

Key Points: 
  • VANCOUVER, B.C., Dec. 21, 2022 /PRNewswire/ -- The digital diabetes management market size reached USD 13.6 Billion in 2021 and is expected to register a CAGR of 12.0% during the forecast period, according to latest analysis by Emergen Research .
  • As a result, the management and treatment of many diseases are depending on the widespread use of information and communication technology (ICT)-based digital health systems, which is driving the adoption of digital diabetes management services in the market.
  • Demand for digital diabetes management devices has significantly increased over the years due to the increasing prevalence of diabetes and obesity around the world.
  • The digital diabetes management market is expected to register a CAGR of 12.0% over the forecast period and revenue is projected to increase from USD 13.6 Billion in 2021 to USD 37.8 Billion in 2030.

New International Consensus on CGM Clinical Trial Metrics Aims to Spur Diabetes Treatment Advances

Retrieved on: 
Tuesday, December 6, 2022
Online, American Diabetes Association, Ljubljana University Medical Centre, International Conference on Population and Development, JDRF, Food, European Association for the Study of Diabetes, Human, Endocrinology, Conference, International Society for Pediatric and Adolescent Diabetes, DCCT, International Society, ATTD, Israel Advanced Technology Industries, Patient, Science, CGM, Collection, CGMS-A, Research, Adolescence, Treatment, Disease, Blood, Obesity, Quality of life, US Food Sovereignty Alliance, European Medicines Agency, Paper, News, The Lancet, TIR, SAN, Pharmaceutical industry, Cryptocurrency, Diabetes

The groundbreaking consensus statement, endorsed by numerous leading US and international diabetes organizations, including the American Association of Clinical Endocrinology, American Diabetes Association, Association of Diabetes Care and Education Specialists, DiabetesIndia, European Association for the Study of Diabetes, International Society for Pediatric and Adolescent Diabetes, Japan Diabetes Society, and JDRF, was published in The Lancet Diabetes & Endocrinology on December 6, 2022.

Key Points: 
  • The groundbreaking consensus statement, endorsed by numerous leading US and international diabetes organizations, including the American Association of Clinical Endocrinology, American Diabetes Association, Association of Diabetes Care and Education Specialists, DiabetesIndia, European Association for the Study of Diabetes, International Society for Pediatric and Adolescent Diabetes, Japan Diabetes Society, and JDRF, was published in The Lancet Diabetes & Endocrinology on December 6, 2022.
  • The article, "Continuous glucose monitoring and metrics for clinical trials: an international consensus statement," is available here .
  • "Standardizing the use of CGM data in clinical trials of diabetes therapies will help ensure that the next generation of treatments are focused on increasing patients' TIR and, therefore, quality of life."
  • As such, earlier this year, the diaTribe Foundation, ATTD, and the Time in Range Coalition convened a group of international experts to discuss and reach consensus on the role of CGMs and CGM-derived metrics in clinical trials for diabetes treatment.

New International Consensus on CGM Clinical Trial Metrics Aims to Spur Diabetes Treatment Advances

Retrieved on: 
Tuesday, December 6, 2022
Online, American Diabetes Association, Ljubljana University Medical Centre, International Conference on Population and Development, JDRF, Food, European Association for the Study of Diabetes, Human, Endocrinology, Conference, International Society for Pediatric and Adolescent Diabetes, DCCT, International Society, ATTD, Israel Advanced Technology Industries, Patient, Science, CGM, Collection, CGMS-A, Research, Adolescence, Treatment, Disease, Blood, Obesity, Quality of life, US Food Sovereignty Alliance, European Medicines Agency, Paper, News, Multimedia, The Lancet, TIR, SAN, Pharmaceutical industry, Cryptocurrency, Diabetes

The groundbreaking consensus statement, endorsed by numerous leading US and international diabetes organizations, including the American Association of Clinical Endocrinology, American Diabetes Association, Association of Diabetes Care and Education Specialists, DiabetesIndia, European Association for the Study of Diabetes, International Society for Pediatric and Adolescent Diabetes, Japan Diabetes Society, and JDRF, was published in The Lancet Diabetes & Endocrinology on December 6, 2022.

Key Points: 
  • The groundbreaking consensus statement, endorsed by numerous leading US and international diabetes organizations, including the American Association of Clinical Endocrinology, American Diabetes Association, Association of Diabetes Care and Education Specialists, DiabetesIndia, European Association for the Study of Diabetes, International Society for Pediatric and Adolescent Diabetes, Japan Diabetes Society, and JDRF, was published in The Lancet Diabetes & Endocrinology on December 6, 2022.
  • The article, "Continuous glucose monitoring and metrics for clinical trials: an international consensus statement," is available here .
  • "Standardizing the use of CGM data in clinical trials of diabetes therapies will help ensure that the next generation of treatments are focused on increasing patients' TIR and, therefore, quality of life."
  • As such, earlier this year, the diaTribe Foundation, ATTD, and the Time in Range Coalition convened a group of international experts to discuss and reach consensus on the role of CGMs and CGM-derived metrics in clinical trials for diabetes treatment.

Scientists Develop 12-Hour Method to Predict Diabetes Onset in Patients Using Artificial Intelligence

Retrieved on: 
Friday, December 2, 2022
Technology, Biotechnology, Diabetes, Health, Artificial Intelligence, Other Science, Other Technology, Research, Software, Hardware, Science, Data Management, Clinical Trials, Consumer Electronics, Consensus, 100 Best Workplaces in Europe, Diabetes, Amanda Ferguson, Type 2, COVID-19, Artificial intelligence, Conference on Neural Information Processing Systems, Inclusion, Type 2 diabetes, Research, Conference, CGM, Sensei, Risk, CGMS-A, Therapy, Human, Severe acute respiratory syndrome coronavirus 2, Glucose, Intelligence, Patient, Ecosystem, Social media, CDC, International Joint Conference on Artificial Intelligence, Prediabetes, Millennials, Biomarker, Physician, Jeon, Science, Blood, Type, IJCAI, Machine learning, Medical device, Pharmaceutical industry, Woman, Paulo, Click, Nature, Health

Scientists at Klick Applied Sciences have discovered a way to transform a continuous glucose monitor (CGM) into a powerful diabetes screening and prevention tool using artificial intelligence.

Key Points: 
  • Scientists at Klick Applied Sciences have discovered a way to transform a continuous glucose monitor (CGM) into a powerful diabetes screening and prevention tool using artificial intelligence.
  • We think CGMs could be used to not just monitor diabetesbut to prevent it altogether.
  • For the study, about 600 patients who identified as healthy, prediabetic, or living with Type 2 diabetes wore a CGM device for an average of 12 days.
  • They also presented earlier findings at the 2018 International Joint Conference on Artificial Intelligence (IJCAI) in Stockholm, Sweden.

Levels Named to Fast Company’s Second Annual List of the Next Big Things in Tech

Retrieved on: 
Thursday, November 17, 2022
Wearables, Mobile Technology, Food, Beverage, Environment, Retail, Food Tech, Software, Medical Devices, Consumer, Data Management, Fitness & Nutrition, Technology, Diabetes, Agriculture, Natural Resources, Health, Apps, Applications, Health Technology, Lifestyle, Metabolism, Agriculture, Prediabetes, Overalls, CGMS-A, Exercise, Food, Conditional sentence, Environment, Infertility, NBA, SpaceX, Diet, Metabolic syndrome, Cleveland Cavaliers, Intelligence, Depression, Sleep, Disorder, TechCrunch, Diabetes, Stanford University, Organization, CGM, Learning, Health, Longevity, Degenerative disease, Renewable energy, Medical device, Netflix, Instacart

Levels , a software company that provides real-time feedback on how food affects your health, today announced it has been named to Fast Companys second annual Next Big Things in Tech list, honoring technology breakthroughs that promise to shape the future of industriesfrom agriculture and environment to productivity and artificial intelligence.

Key Points: 
  • Levels , a software company that provides real-time feedback on how food affects your health, today announced it has been named to Fast Companys second annual Next Big Things in Tech list, honoring technology breakthroughs that promise to shape the future of industriesfrom agriculture and environment to productivity and artificial intelligence.
  • Our company is laser focused on reversing these preventable metabolic trends, which starts with awareness of the problem.
  • Fast Companys recognition is a great step towards achieving this goal.
  • Levels closed its $38 million Series A earlier this year with a portion of the raise driven by member crowdfunding.

Point of Care Diagnostics and Continuous Monitoring: IDTechEx Reflects on Trends in 2022

Retrieved on: 
Wednesday, November 2, 2022
Players, Intel Active Management Technology, Respiratory syncytial virus, DNA, Triage, Pharmacy, CGM, Industry, COVID-19, Holter, Subscription business model, Temperature, Point-of-care testing, FDA, RF, RPM, Criticism of the Food and Drug Administration, Transducer, Intelligence, Disease management, Atrial fibrillation, Infection, Research, Apple, Apple Watch, POCT, Technology, Digital, Alphabet, Consultant, Patient, COVID-19 testing, Neutropenia, Electronics, ECG, Prediabetes, Cancer, Time, Hypertension, Disease, HIV disease progression rates, Infarction, Arrhythmia, Stroke, Degenerative disease, Fatigue, Diabetes, Pressure, Health, Health status of Asian Americans, Parkinson's disease, RSV, MCT, Blood, Food, Conditional sentence, POC, CGMS-A, Pharmaceutical industry, Medical imaging, Fitbit, Valencell, PD

In diabetes, patients are able to monitor their blood glucose via glucose test strips and continuous glucose monitors (CGMs) at home and on the move.

Key Points: 
  • In diabetes, patients are able to monitor their blood glucose via glucose test strips and continuous glucose monitors (CGMs) at home and on the move.
  • For more information about biosensors across bioreceptors, transducers, and applications, please refer to the IDTechEx report " Biosensors for Point-of-Care Diagnostics 2022-2032: Technology, Opportunities, Players and Forecasts ".
  • IDTechEx offer reports on topics spanning multiple fields including wearable technologies, digital health, DNA sequencing, antimicrobial technology,and many more.
  • IDTechEx guides your strategic business decisions through its Research, Subscription and Consultancy products, helping you profit from emerging technologies.

Point of Care Diagnostics and Continuous Monitoring: IDTechEx Reflects on Trends in 2022

Retrieved on: 
Wednesday, November 2, 2022
Players, Intel Active Management Technology, Respiratory syncytial virus, DNA, Triage, Pharmacy, CGM, Industry, COVID-19, Holter, Subscription business model, Temperature, Point-of-care testing, FDA, RF, RPM, Criticism of the Food and Drug Administration, Transducer, Intelligence, Disease management, Atrial fibrillation, Infection, Research, Apple, Apple Watch, POCT, Technology, Digital, Alphabet, Consultant, Patient, COVID-19 testing, Neutropenia, Electronics, ECG, Prediabetes, Cancer, Time, Hypertension, Disease, HIV disease progression rates, Infarction, Arrhythmia, Stroke, Degenerative disease, Fatigue, Diabetes, Pressure, Health, Health status of Asian Americans, Parkinson's disease, RSV, MCT, Blood, Food, Conditional sentence, POC, CGMS-A, Pharmaceutical industry, Medical imaging, Fitbit, Valencell, PD

In diabetes, patients are able to monitor their blood glucose via glucose test strips and continuous glucose monitors (CGMs) at home and on the move.

Key Points: 
  • In diabetes, patients are able to monitor their blood glucose via glucose test strips and continuous glucose monitors (CGMs) at home and on the move.
  • For more information about biosensors across bioreceptors, transducers, and applications, please refer to the IDTechEx report " Biosensors for Point-of-Care Diagnostics 2022-2032: Technology, Opportunities, Players and Forecasts ".
  • IDTechEx offer reports on topics spanning multiple fields including wearable technologies, digital health, DNA sequencing, antimicrobial technology,and many more.
  • IDTechEx guides your strategic business decisions through its Research, Subscription and Consultancy products, helping you profit from emerging technologies.

Providers Now Have Free Access to Latest Diabetes Technology in One Place

Retrieved on: 
Thursday, October 13, 2022
BSN, Insurance, Therapy, Education, Patient, Minnesota Advanced Practice Registered Nursing, MBA, Art, Multimedia, RN, Doctor of Public Health, Glucose meter, CGMS-A, CGM, Association, Diabetes, CE, Pharmaceutical industry, Medicine, Medical device

CHICAGO, Oct. 13, 2022 /PRNewswire/ -- All healthcare professionals caring for people with diabetes now have access to vital information about the latest diabetes technology in one place through the Association of Diabetes Care & Education Specialists' (ADCES) newly revamped danatech website.

Key Points: 
  • CHICAGO, Oct. 13, 2022 /PRNewswire/ -- All healthcare professionals caring for people with diabetes now have access to vital information about the latest diabetes technology in one place through the Association of Diabetes Care & Education Specialists' (ADCES) newly revamped danatech website.
  • Site visitors can also access training and education on the devices, including many for continuing education (CE/CME) credit.
  • "The number of people with diabetes is skyrocketing and there aren't nearly enough specialists to treat them all, healthcare professionals in multiple practice settings are caring for people with diabetes," said Leslie Kolb, DrPH, MBA.
  • "But many are not familiar with the multitude of new technologies and devices available to those who need them the most.